Oregovomab

Identification

Name
Oregovomab
Accession Number
DB04964
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

Protein structure
Db04964
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • B43.13
  • MOAB B43.13
  • Monoclonal antibody B43.13
  • Oregovamab
International/Other Brands
OvaRex
Categories
UNII
HX101E7L6S
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in ovarian cancer.

Structured Indications
Not Available
Pharmacodynamics

Oregovomab is well tolerated and induces multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit has been observed in patients mounting a T-cell response to CA125 and/or autologous tumor. Vaccination with oregovomab may stimulate a host cytotoxic immune response against tumor cells that express CA125.

Mechanism of action

Oregovomab targets the circulating tumour-associated antigen CA 125, which is shed from the surface of human ovarian cancer cells; the antibodies induce broad cellular and humoral immune responses against CA 125 via complex formation. Unlike free CA 125, CA 125-oregovomab complexes can prime dendritic cells, leading to downstream activation of T cells.

TargetActionsOrganism
UMucin-16Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Oregovomab.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Oregovomab.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Oregovomab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Oregovomab.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Oregovomab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Oregovomab.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Oregovomab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Oregovomab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Oregovomab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Oregovomab.Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Oregovomab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Oregovomab.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Oregovomab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Oregovomab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Oregovomab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Oregovomab.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Oregovomab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Oregovomab.Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Oregovomab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Oregovomab.Approved
Food Interactions
Not Available

References

General References
  1. Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65. [PubMed:15268682]
  2. Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF: CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004 Aug;94(2):340-51. [PubMed:15297171]
  3. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD: A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34. [PubMed:16343178]
  4. Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83. [PubMed:17073521]
External Links
PubChem Substance
347909863

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingOtherAdvanced Ovarian Cancer / Cancer, Ovarian / Neoplasms, Ovarian / Ovarian Cancer Stage III / Ovary Cancer / Recurrent Ovarian Cancer1
1, 2TerminatedTreatmentNeoplasms, Ovarian1
2Active Not RecruitingTreatmentNeoplasms, Ovarian1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma / Stage I Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage II Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentNeoplasms, Ovarian1
2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer2
3TerminatedTreatmentCancer, Ovarian1
Not AvailableWithdrawnTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Gene Name
MUC16
Uniprot ID
Q8WXI7
Uniprot Name
Mucin-16
Molecular Weight
1519158.08 Da
References
  1. Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65. [PubMed:15268682]
  2. Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83. [PubMed:17073521]

Drug created on October 21, 2007 16:23 / Updated on November 06, 2017 06:45